A H3K27M-targeted vaccine in adults with diffuse midline glioma
Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient
…, P Eisele, N Grassl, I Mildenberger, K Sahm… - Science …, 2024 - science.org
H3K27M, a driver mutation with T and B cell neoepitope characteristics, defines an aggressive
subtype of diffuse glioma with poor survival. We functionally dissect the immune response …
subtype of diffuse glioma with poor survival. We functionally dissect the immune response …
[HTML][HTML] In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
…, R Santarella-Mellwig, M Kilian, K Jähne, K Sahm… - Theranostics, 2023 - ncbi.nlm.nih.gov
Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies
including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric …
including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric …
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
…, W Müller, E Sperk, LC Schmeel, K Sahm… - Nature …, 2024 - nature.com
The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT)
by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of …
by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of …
[PDF][PDF] Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
…, A Unterberg, M Bendszus, K Sahm… - Neuro-oncology …, 2020 - academic.oup.com
Background Molecular profiling allows tumor classification as well as assessment of diagnostic,
prognostic, and treatment-related molecular changes. Translation into clinical practice …
prognostic, and treatment-related molecular changes. Translation into clinical practice …
Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma
Purpose: Primary central nervous system (CNS) gliomas can be classified by characteristic
genetic alterations. In addition to solid tissue obtained via surgery or biopsy, cell-free DNA (…
genetic alterations. In addition to solid tissue obtained via surgery or biopsy, cell-free DNA (…
Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma
Effectors from the immune system can modulate the course and possibly the early development
of gliomas. We, therefore, hypothesized that autoimmune diseases associated with …
of gliomas. We, therefore, hypothesized that autoimmune diseases associated with …
Blocking tumor-associated immune suppression with BAY-218, a novel, selective aryl hydrocarbon receptor (AhR) inhibitor
…, H Irlbacher, D Stoeckigt, R Carretero, K Sahm… - Cancer Research, 2019 - AACR
Tumor cells co-opt multiple pathways in order to evade attack by infiltrating immune cells. One
such mechanism is the upregulation of indole-2,3-dioxygenase (IDO1) and/or tryptophan-2…
such mechanism is the upregulation of indole-2,3-dioxygenase (IDO1) and/or tryptophan-2…
Neoepitope-specific vaccination of a patient with diffuse midline glioma targeting H3K27M induces polyclonal B and T cell responses across diverse HLA alleles
H3K27M, a driver mutation with T- and B-cell neoepitope characteristics, defines an
aggressive subtype of diffuse glioma with poor survival. We functionally dissect the immune …
aggressive subtype of diffuse glioma with poor survival. We functionally dissect the immune …
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
Introduction Diffuse midline gliomas (DMG) are universally lethal central nervous system tumors
that carry almost unanimously the clonal driver mutation histone-3 K27M (H3K27M). The …
that carry almost unanimously the clonal driver mutation histone-3 K27M (H3K27M). The …
